(Q34498202)

2 August 2017

1 reference

title

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer (English)

1 reference

2 August 2017

1 reference

Eleftherios P. Diamandis

3

object named as

Eleftherios P Diamandis

1 reference

2 August 2017

Klaus Jung

2

0 references

Stefan A Loening

6

object named as

Stefan A Loening

1 reference

2 August 2017

Carsten Stephan

1

1 reference

2 August 2017

Harry G Rittenhouse

4

1 reference

2 August 2017

Michael Lein

5

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

59

1 reference

2 August 2017

2-8

1 reference

2 August 2017

1

1 reference

2 August 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

The new human tissue kallikrein gene family: structure, function, and association to disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Human kallikrein 10: a novel tumor marker for ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Percent free prostate-specific antigen for first-time prostate biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Comparison of the Clinical Validity of Free Prostate–Specific Antigen, Alpha–1 Antichymotrypsin–Bound Prostate–Specific Antigen and Complexed Prostate–Specific Antigen in Prostate Cancer Diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901449-2

7 January 2021

10.1016/S0090-4295(01)01449-2

Identifiers

DOI

1 reference

2 August 2017

1 reference